Parkinson’s disease (PD) is primarily marked by the gradual loss of dopamine-producing neurons, which are vital for controlling movement, mood, and motivation. While traditional PD therapies target symptoms, stem cell research is exploring whether regenerating dopamine neurons could offer a more fundamental solution.
Two early-phase clinical trials, published in Nature, examined the safety and initial outcomes of transplanting stem cell-derived progenitor cells into the brains of people with PD. These cells, either from induced pluripotent stem (iPS) cells or human embryonic stem (hES) cells, were inserted into the putamen.
The studies involved 19 participants—7 in the Japan-based iPS trial and 12 in the U.S./Canada hES trial. Participants received either a low or high dose of the cells and were monitored for up to two years. All received immunosuppressive treatment to help prevent rejection of the transplanted cells.
Key findings include:
- No serious adverse events were linked directly to the cell transplants.
- MRI scans showed no signs of tumor formation.
- Involuntary movements (dyskinesias), a known risk from past attempts, were not observed.
Symptom changes and dopamine activity were also tracked:
- In the iPS group, most participants showed improvement on standard Parkinson’s motor scales, with some also demonstrating a 44.7% increase in dopamine activity in the brain region targeted by the therapy.
- In the hES group, brain imaging suggested cell survival and potential function, and higher-dose participants improved by an average of 23 points on PD motor scoring (off medication).
Anyone considering clinical trials should always consult their medical team, ensure study transparency, and avoid trials that charge fees or lack proper consent documentation.
